ATMP clinical trial specialists

Seamless clinical trial set-up, delivery and completion

Your trusted CRO partner for ATMP trials in the UK

Our experienced in-house team has broad knowledge in clinical studies in cell and gene therapy (ATMP). We have delivered first-in- human and first-in-patient clinical trials in the UK, with a focus on rare disease, oncology, haematology and ophthalmology.

We are a full service Clinical Research Organisation (CRO) offering a unique ‘ mix-and-match’ service model – allowing you to engage the specific services you need which are tailored to each of your projects.

Recognising the bespoke needs of our client, we provide a value-added partnership, especially during the early setup phase of the trial when your internal teams and infrastructure may still be developing. As your CRO partner we will work collaboratively and transparently with you to ensure the initial stages of the trial are right,  laying the foundations for long term success in your commercial pathway.

Tap into our local knowledge and expertise

  • Extensive UK regulatory knowledge
  • Phase 1 “fast track” approvals
  • Product traceability
  • Study-specific site feasibility
  • Logistic planning and risk mitigation
  • Access to MHRA licenced facilities and apheresis sites
  • Access to NHS approved centre handling CAR T products
  • Optimal site capabilities – investigators, site personnel, pharmacies, nuclear medicine
  • Access to manufacturing and Qualified Persons

Achieve shared success through collaboration and transparency

At PHARMExcel, we foster strong, collaborative relationships with our sponsors, ensuring proactive communication and a firm commitment to understanding your needs. Due to our company size, the team introduced during initial interactions remains consistent throughout your project, fostering stability and accountability for the trial.

"The most collaborative CRO I’ve worked with. PHARMExcel bothered to know us as a client and understands our studies inside out, making it an efficient and friendly partnership. "

Prof. Mark Lowdell, CSO INmuneBio Inc

Gain peace of mind from our quality & risk-based approach

  • Patient-centric study design
  • ATMP risk & safety management plans
  • ISO certified Quality Management System
  • Rapid development of study-specific procedures
  • Risk based monitoring methods
  • ATMP experienced CRAs
  • Experienced clinical quality auditors

Specialists in academic & commercial ATMP trials

Our recent clinical trials running in the UK and Europe include:


Phase I, Cell Therapy
Myelodysplastic Syndrome
3 UK sites, 1 EU site


Phase I, Device-ATMP Combination
Ovarian Cancer
2 UK sites

Wharton's Jelly

Phase I, Tissue Engineered
Cardiac (Paediatric)
1 UK site

Gene Transfer

Phase I, Gene Therapy
Haemophilia B
1 UK and 1 USA site


Phase I/IIa, Targeted Therapy & Stem Cell Transplant
5 UK sites

We’re part of the largest cell and gene cluster outside the USA.

We’re here to help